Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
May 27, 2025
In the News
Foley's Silicon Valley Corporate Additions Featured in Legal Press
Foley & Lardner LLP partners Gurpreet Bal and Shaalu Mehra are highlighted in legal press for their recent arrival to the firm.
May 21, 2025
In the News
Nathaniel Lacktman Shares Insight on Virtual Second Opinion Programs
Foley & Lardner LLP partner Nathaniel Lacktman highlighted considerations for virtual second-opinion programs (VSOs) in the Physician's Weekly article, "Navigating Licensure Risks in Virtual Second-Opinion Programs."
May 16, 2025
In the News
Foley's East Coast Litigation Additions Highlighted in Legal Press
Foley & Lardner LLP partners Kenneth Breen, Phara Guberman, and Joseph Dowdy are featured across legal press for their recent move to the firm.